Itepekimab Failure A Setback For Sanofi And Regeneron

(8min)

Summary

  • Itepekimab's inconsistent phase 3 results represent a setback for Regeneron Pharmaceuticals and Sanofi.
  • The results do not support regulatory submissions and a 3-4 year approval delay, and lower peak sales potential looks like a best-case scenario for itepekimab.
  • Regeneron faces a greater impact, as it is losing an important growth driver in the second half of the decade.
  • Sanofi is better positioned to absorb the loss, but it should leverage recent cash inflows from the Opella spinoff to expand its pipeline and product portfolio.
  • Verona Pharma emerges as a clear winner, with improved prospects for Ohtuvayre after itepekimab’s disappointing results.
  • Looking for a helping hand in the market? Members of Growth Stock Forum get exclusive ideas and guidance to navigate any climate. Learn More »

Straws arranged into a falling graph

Richard Drury

Shares of Sanofi (NASDAQ:SNY) and its partner Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) are down today after the companies announced that itepekimab met the primary endpoint in only one of the two phase 3

I publish my best ideas and top coverage in the Growth Stock Forum. We focus on attractive risk/reward situations and track each of our portfolio stocks, Top Picks and Trading Ideas closely. If you're interested in finding great growth stocks, consider signing up to Growth Stock Forum. Join by June 9, to lock in the current rates before prices increase.

This article was written by

9.21K Followers

ONeil Trader is a former stockbroker turned full-time independent investor. He focuses on finding growth and biotech stocks with significant growth potential and calculates ideas in large part based on best risk-adjusted returns.

He leads the investing group Growth Stock Forum which features: a model portfolio of 15-20 names updated regularly, a top picks list of up to 10 stocks that are expected to perform well in the current calendar year, trading ideas that target both short-term and medium-term moves, and chat with community dialogue and for questions. Learn More.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article reflects the author's opinion and should not be regarded as a buy or sell recommendation or investment advice in any way.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About SNY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on SNY

Related Stocks

SymbolLast Price% Chg
SNY
--
REGN
--
SNYNF
--
GCVRZ
--